Business Wire

EXSCIENTIA

10.3.2022 14:02:09 CET | Business Wire | Press release

Share
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery

Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage drug discovery research – primarily conducted within academic labs – and potentially leverage those outputs to bring therapies to patients sooner. The program offers applicants resources to explore, identify and rapidly advance novel drug targets by leveraging Oxford TDI’s expertise in developing robust, disease-relevant, predictive screening assays and Exscientia’s AI personalised medicine design capabilities.

“Academic research has and will continue to play a critical role in the development and advancement of medicine, and this partnership is a shining example of how industry and academia can come together to bridge a traditional gap in the drug development cycle,” said Sir Peter Ratcliffe, FRS, FMedSci, Director of the Oxford TDI within the Nuffield Department of Medicine and winner of the 2019 Nobel Prize in Medicine. “Despite the multitude of advancements in using genetics, genomics, cell and chemical biology to improve target discovery, we believe we’ve only scratched the surface in terms of available assays that could be translated into meaningful therapies for patients.”

Assay submissions will be evaluated and selected by the Xcellomics Scientific Committee and will be developed, produced and validated within Oxford TDI’s advanced cell screening facility using a range of phenotypic and functional genomic outputs that leverage Exscientia’s technology platform. The Xcellomics Board provides oversight and is comprised of members from Exscientia and Oxford TDI, and is chaired by Exscientia’s founder and CEO, Andrew Hopkins, DPhil.

Successful projects will be progressed using Exscientia’s proprietary AI-driven platform with the aim of rapidly identifying potential targets for potential new medicine programmes. Therapeutic area focus will rotate every six months, beginning with a focus on oncology and immuno-oncology, although “blue sky” submissions will be accepted on a rolling basis. Data and intellectual property will be co-owned by the researcher and the Xcellomics program.

“Exscientia’s roots started in academia, and we remain committed to supporting and advancing the innovative research happening at these institutions around the world,” said Denise Barrault, Director, Portfolio Management at Exscientia. “We believe that our partnership with the University of Oxford Target Discovery Institute will help unearth new science and potentially translate and advance the most promising ideas into tomorrow’s new medicines.”

An online informational event will be held Wednesday, March 23 at 1:00 p.m. GMT. More information on the event can be found at : https://www.xcellomics.com/launch-event

About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Vienna, Dundee, Boston, Miami, Cambridge (UK) and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI .

About OXFORD TDI
Target discovery helps identify drug targets, molecules or molecular interactions at a critical point in a disease-causing pathway that are predicted to being amenable to therapeutic manipulation. The centre aims to link recent advances in genetics, genomics, cell and chemical biology for improved drug target discovery. A more specific focus for refining and validating such targets will provide a better link between traditional "open ended" academic processes to biomedical research and the need of the pharmaceutical industry for accurately defined targets to accelerate drug development.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations regarding the activities and potential benefits of the Xcellomics programme. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the Xcellomics program discussed above will be successful in identifying or developing novel assays. The success of the program is subject to numerous factors, many of which are beyond the control of Exscientia, including, without limitation, the interest of academic researchers in the Xcellomics program and their willingness to collaborate with us. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release

New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud

The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release

The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f

IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 17:00:00 CET | Press release

IQM quantum computers already run at leading supercomputing centers, including Oak Ridge National Laboratory (ORNL), VTT Technical Research Centre of Finland, the Leibniz Supercomputing Centre (LRZ) and CINECA, with users reaching them through Slurm. IQM supports NVIDIA’s investment in making quantum processors a schedulable resource in supercomputing centers by integrating IQM quantum computers with Slurm. IQM’s partner MQSC (Munich Quantum Software Company) has demonstrated the MQSC Orchestrator scheduling IQM systems through the new Slurm capability. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making q

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release

Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye